Gainers

• Picard Medical (AMEX:PMI) shares moved upwards by 82.7% to $9.38 during Tuesday's regular session. The market value of their outstanding shares is at $10.5 million. As per the news, the Q2 earnings report came out 4 days ago.
• Autonomix Medical (NASDAQ:AMIX) stock rose 52.47% to $8.19. The market value of their outstanding shares is at $5.2 million.
• ZeroStack (NASDAQ:ZSTK) stock moved upwards by 27.89% to $6.47. The company's market cap stands at $12.2 million.
• Tenax Therapeutics (NASDAQ:TENX) shares moved upwards by 25.13% to $2.31. The market value of their outstanding shares is at $49.0 million.
• RenovoRx (NASDAQ:RNXT) stock increased by 22.4% to $1.53. The market value of their outstanding shares is at $56.4 million.
• Bristol-Myers Squibb Company Celegne Contingent Value Rights (NYSE:CELGR) stock moved upwards by 20.2% to $0.12.

Losers

• OSR Health (NASDAQ:OSRH) shares fell 51.3% to $0.12 during Tuesday's regular session. The company's market cap stands at $8.7 million.
• CDT Equity (NASDAQ:CDT) stock fell 15.47% to $2.1. The market value of their outstanding shares is at $1.9 million.
• AIxCrypto Hldgs (NASDAQ:AIXC) stock declined by 12.28% to $0.82. The market value of their outstanding shares is at $18.9 million.
• Jupiter Neurosciences (NASDAQ:JUNS) stock fell 11.84% to $4.99. The market value of their outstanding shares is at $7.5 million.
• Profusa (NASDAQ:PFSA) stock fell 10.06% to $4.12. The company's market cap stands at $2.7 million. The company's, Q2 earnings came out 3 days ago.
• Stablecoin Development (AMEX:SDEV) stock fell 9.83% to $1.01. The market value of their outstanding shares is at $30.3 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.